Clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of domestic and foreign authoritative experts to provide accurate diagnosis and treatment programs. Treatment and management of anti-synthetic enzyme syndrome accompanying antibodies require individual development, usually including multidimensional management, including pharmacotherapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many autoimmune and rheumatic immune diseases that have previously been difficult to treat.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely regimens according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of anti-synthetase syndrome supplements. The platform serves China's International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.